Saturday 17 October 2026
Export SPRY’s income statement to Excel — free account
ARS Pharmaceuticals, Inc.
SPRY Healthcare Biotechnology
ARS Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $84.3 million, down 5.46% from fiscal 2024. In the quarter to June 2026, revenue grew 114.2%, EPS fell 37.0%, free cash flow fell 53.7% and total debt rose 138.5%, each against the same quarter a year earlier.
4.02
0.05
−1.23%
Follow SPRY
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | — | — | 2 | 5 | 1 |
P/E ratio |
— | — | — | — | 0.00 | 0.00 | 0.00 | 131.88 | 0.00 |
P/S ratio |
— | — | — | — | 0.00 | 223.54 | 1,302.21 | 11.47 | 13.63 |
Altman Z-Score |
— | — | — | — | 6.03 | 24.29 | 128.38 | 7.30 | 1.32 |
Altman Z″-Score (non-manufacturers) |
— | — | — | — | 4.06 | 38.12 | 102.46 | 7.46 | (1.13) |
P/FCF ratio |
— | — | — | — | 0.00 | 0.00 | 0.00 | 78.76 | 0.00 |
Beneish M-Score |
— | — | — | — | — | 3,877.59 | — | — | (0.44) |
P/Operating CF |
— | — | — | — | 6.89 | (16.41) | (30.53) | 24.35 | (26.41) |
P/B ratio |
— | — | — | — | 0.00 | 1.23 | 2.30 | 3.98 | 10.05 |
Price to Tangible BV |
— | — | — | — | 0.00 | 1.23 | 2.30 | 4.10 | 11.51 |
EV/Sales |
— | — | — | — | 0.00 | 44.26 | 743.94 | 8.73 | 12.72 |
EV/EBITDA |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | — | — | — | (7.84) | (1.66) | (5.12) | 57.47 | (6.28) |
EV/FCF |
— | — | — | — | (7.81) | (1.65) | (5.11) | 59.96 | (5.75) |
Quick Ratio |
— | 3.92 | 0.56 | 40.26 | 7.34 | 50.59 | 95.51 | 13.75 | 6.91 |
Current Ratio |
— | 4.04 | 0.59 | 40.69 | 7.42 | 51.01 | 96.92 | 14.26 | 7.28 |
Net Debt/EBITDA |
— | 0.74 | 0.22 | 11.89 | 2.87 | 7.79 | 3.07 | 23.85 | 0.42 |
Debt/Assets |
0.00% | 28.08% | 30.97% | 0.80% | 8.02% | 0.09% | 0.00% | 19.76% | 51.43% |
Debt/Equity |
— | 0.43 | (0.86) | 0.01 | 0.11 | 0.00 | 0.00 | 0.27 | 1.47 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.02 | 0.01 | 0.00 | 0.31 | 0.25 |
Operating CF/Net income |
— | 0.96 | 0.79 | 0.95 | 0.87 | 1.16 | 1.09 | 1.66 | 1.00 |
Capex/Depreciation |
— | 0.00 | (0.16) | (1.37) | (0.26) | (0.62) | 0.03 | 1.12 | 1.97 |
Interest Coverage |
— | (852.09) | — | — | — | — | — | — | — |
| — | 37.50% | 51.13% | (20.33%) | (11.51%) | (28.71%) | (21.59%) | 3.35% | (92.38%) | |
| — | (127.63%) | (110.97%) | (16.05%) | (8.87%) | (20.23%) | (21.13%) | 2.80% | (50.50%) | |
ROIC |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (1,758.33%) | (15.85%) | (296.82%) |
Return on Tangible Assets |
— | (81.19%) | 394.06% | (8.61%) | (38.47%) | (12.72%) | (23.65%) | 2.62% | (69.05%) |
Average Days of Receivables |
— | — | — | — | 0.07 | 279.85 | 0.00 | 33.47 | 109.78 |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 368.20% | 1,396.35% | 67,553.33% | 21.96% | 15.64% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 85.13% | 1,402.43% | 157,613.33% | 80.40% | 273.05% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.04 |
Share Based Compensation of Revenue |
— | — | 0.00% | 0.00% | 51.38% | 444.00% | 30,783.33% | 16.30% | 26.22% |
Graham Net Nets |
— | — | — | — | 0.23 | 0.80 | 0.43 | 0.23 | 0.06 |
Graham Number |
— | — | — | — | 4.13 | 0.00 | 0.00 | 2.18 | 0.00 |
Earnings Yield |
— | — | — | — | (10.49%) | (10.31%) | (10.22%) | 0.76% | (15.02%) |
Free Cash Flow Yield |
— | — | — | — | (9.16%) | (11.97%) | (11.19%) | 1.27% | (16.25%) |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 0.19 | 0.03 | 0.00 | 0.92 | 0.86 |
Operating CF per Share |
— | (0.51) | (28.59) | (10.73) | (0.61) | (1.00) | (0.62) | 0.14 | (1.73) |
Capex per Share |
— | 0.00 | (0.15) | (0.32) | 0.00 | 0.00 | 0.00 | (0.08) | (0.08) |
Free Cash Flow per Share |
— | (0.51) | (28.74) | (11.04) | (0.61) | (1.01) | (0.62) | 0.06 | (1.82) |
Cash per Share |
— | 0.61 | 15.09 | 132.96 | 2.08 | 6.87 | 2.40 | 3.24 | 2.49 |
Shareholders Equity per Share |
— | 0.55 | (8.48) | 131.69 | 1.55 | 6.83 | 2.42 | 2.65 | 1.16 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 0.55 | (8.48) | 131.69 | 1.55 | 6.83 | 2.42 | 2.65 | 1.16 |
Free Cash Flow |
— | (16.87) | (18.99) | (32.11) | (17.62) | (40.28) | (59.44) | 5.49 | (179.06) |
Working Capital |
— | 15.63 | (7.40) | 381.06 | 52.54 | 272.26 | 229.34 | 310.86 | 245.75 |
Capital Expenditures |
— | (0.45) | (0.10) | (0.92) | (0.05) | (0.20) | (0.17) | (8.06) | (8.20) |
Net Current Asset Value |
— | 11.43 | (10.72) | 378.73 | 44.05 | 269.15 | 229.30 | 239.94 | 71.50 |
EV/EBIT |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
— | — | 0.00 | 0.00 | 0.01 | 0.15 | 5.83 | 0.09 | 0.10 |
Price to Operating Income |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | |||||||||
Depreciation/Fixed assets |
— | 0.24 | 0.47 | 0.41 | 2.96 | 0.97 | (11.80) | (6.73) | (1.69) |
Cash ROIC |
— | (36.61%) | (206.03%) | (4.16%) | (16.05%) | (7.36%) | (12.95%) | 0.86% | (33.93%) |
Accounts Receivable Turnover |
— | — | — | — | 0.00 | 2.61 | 0.00 | 19.41 | 5.03 |
Accounts Payable Turnover |
— | 0.66 | 0.72 | 0.56 | 0.07 | 0.08 | 0.00 | 0.08 | 0.67 |
Inventory Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 3.01 |
Average Days of Payables |
— | 199.21 | 830.58 | 551.34 | 5,324.20 | 5,642.05 | 0.00 | 8,533.23 | 678.21 |
Days of Inventory on Hand |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 1,947.16 | 149.57 |
Average Receivables |
— | — | — | — | — | 0.51 | — | 4.59 | 16.76 |
Average Payables |
— | 2.15 | 2.15 | 3.05 | 2.85 | 4.02 | 3.54 | 12.50 | 30.39 |
Average Inventory |
— | — | — | — | — | — | — | — | 6.79 |
Average Assets |
— | 13.77 | 21.60 | 205.23 | 228.13 | 171.44 | 257.31 | 292.17 | 339.40 |
Average Common Equity |
— | (46.88) | (46.88) | 162.05 | 175.80 | 120.81 | 251.82 | 243.78 | 185.53 |
Columns are period end dates